103
Participants
Start Date
July 31, 2008
Primary Completion Date
February 28, 2010
Study Completion Date
March 31, 2010
ISIS 353512
50 mg via 2 hour IV infusion, single dose
ISIS 353512
50 mg via 2 hour IV infusion, 6 doses over 22 days
ISIS 353512
50 mg via SC injection, single dose
ISIS 353512
50 mg via SC injection, 6 doses over 22 days
ISIS 353512
2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
ISIS 353512
100 mg via 2 hour IV infusion, single dose
ISIS 353512
200 mg via 2 hour IV infusion, single dose
ISIS 353512
100 mg via SC injection, single dose
ISIS 353512
200 mg via SC injection, single-dose
ISIS 353512
100 mg via 2 hour IV infusion, 6 doses over 22 days
ISIS 353512
200 mg via 2 hour IV infusion, 6 doses over 22 days
ISIS 353512
100 mg via SC injection, 6 doses over 22 days
ISIS 353512
200 mg via SC injection, 6 doses over 22 days
ISIS 353512
100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
ISIS 353512
200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
ISIS 353512
2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
Anapharm, Montreal
Lead Sponsor
Collaborators (1)
Anapharm
INDUSTRY
Ionis Pharmaceuticals, Inc.
INDUSTRY